Letter to the EditorSuccessful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome
Section snippets
Funding statement
This work was supported by funding to M.A. from the Advanced Research and Development Programs for Medical Innovation (AMED-CREST) (19gm0910002h0105) of the Japan Agency for Medical Research and Development (AMED). This work was also supported by Grant-in-Aid for Scientific Research (B) (18H02832) from the Japan Society for the Promotion of Science (JSPS) and by Health and Labor Sciences Research Grants; Research on Intractable Diseases (20FC1052) from the Ministry of Health, Labor and Welfare
Declaration of Competing Interest
The authors have no conflict of interest to declare.
Acknowledgements
We would like to thank Mr. Koji Itakura for his help with the light microscopic and scanning electron microscopic observations.
References (10)
- et al.
Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation bySPINK5-derived Peptides
J. Invest. Dermatol.
(2002) - et al.
Hair abnormality in Netherton syndrome observed under polarized light microscopy
J. Am. Acad. Dermatol.
(2020) Profiling immune expression to consider repurposing therapeutics for the ichthyoses
J. Invest. Dermatol.
(2019)- et al.
Successful dupilumab treatment of an adult with Netherton syndrome
Clin. Exp. Dermatol.
(2020) - et al.
Treatment of netherton syndrome with dupilumab
JAMA Dermatol.
(2020)
There are more references available in the full text version of this article.
Cited by (0)
© 2021 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.